Pharma's Almanac TV
PA TV
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Immunotherapy
38 Articles Available
1
2
Can't find what you're looking for? Try our
advanced search
.
Partnership
Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies
PR-M05-20-NI-041
PR-M03-20-NI-036
Vaccitech and Oxford University Announce Promising Phase 2a Data on Prostate Cancer Immunotherapy
PR-M03-20-NI-036
In Conversation
In Conversation: NantKwest — Harnessing Natural Killer Cells to Treat Cancer
PAP-Q1-20-CL-016
Immunotherapy
NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Combination Immunotherapy in Triple Negative Breast Cancer
PR-M12-19-NI-022
Launch
Werewolf Therapeutics Launches with $56M Series A Financing to Develop Transformative Immuno-Stimulatory Cancer Medicines
PR-M11-19-NI-024
CAR-T Immunotherapy
Cabaletta Bio Announces Presentation of Preclinical Data Showing Specific CAAR T Activity against Anti-MuSK Expressing B Cells
PR-M10-19-NI-024
IND Approval
ActoBio Therapeutics™ Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients' Tolerance of Gluten
PR-M09-19-NI-006
Alliance
Nimbus Therapeutics and Celgene Expand Alliance to Immunotherapy in Oncology
PR-M07-19-NI-027
Immunotherapy
Researchers Report SX-682 Could Enhance Multiple Forms of T Cell-Based Immunotherapies in Solid Tumors
PR-M04-19-NI-040
Investment
Portage Makes Additional Investment in Stimunity S.A, a Paris-based Cancer Immunotherapy Company
PR-M03-19-NI-081
Immunotherapy
Collaborating for Immunotherapy Development
PAP-Q1-2019-NI-007
Immunotherapy
AIVITA Identifies Mechanism to Enhance Patient Response Rate to Next Generation Cancer Stem Cell Immunotherapy
PR-M02-19-NI-031
Immunotherapy
Global Cancer Immunotherapy Market: Focus on Pharmaceutical Products, Therapeutic Indication, Competitive Landscape and Region - Analysis and Forecast, 2018-202
PR-M02-19-NI-024
Immuno-oncology
GE Healthcare, Vanderbilt University Medical Center Partner for Safer, More Precise Immunotherapy Cancer Treatment
PR-M01-19-NI-023
Immunotherapy
Global Cancer Immunotherapy Market 2017-2027 Featuring Leading Players - Pfizer, Merck, Amgen and Roche
PR-M12-18-NI-012
Cell Therapy
Immunotherapy Pioneers a Unveil Updated Efficacy Data of Tisagenlecleucel, plus Checkpoint Inhibitor Research to Boost Response of CAR T-cell Gene Immunotherapy
PR-M12-18-NI-011
Immunotherapy
Patient Weight Can Impact the Effectiveness of Cancer Immunotherapies
PAO-M11-18-NI-022
Immunotherapy
I-Mab and Genexine Announce China IND Approval for Innovative Immunotherapy
PR-M11-18-NI-014
Immunotherapy
Guardant Health Presents Data on Immunotherapy-related Biomarkers MSI and TMB in blood of advanced cancer patients
PR-M10-18-NI-075
Immunotherapy
eTheRNA Opens State-of-the-art Manufacturing Facility in Belgium to Support the Development of its TriMix-based mRNA Cancer Immunotherapies
PR-M10-18-NI-042
Immunotherapy
Increasing Number of Cancer Cases to Fuel the Global Cancer Immunotherapy Market Growth
PR-M10-18-NI-025
Immunotherapy
Nobel Prize in Medicine Goes to Immunotherapy Developers
PAO-M10-18-NI-003
Immunotherapy
Cancer Immunotherapy Treatment Market on the Rise as R&D Increases
PR-M09-18-NI-086
Immunotherapy
New Nature Medicine Study Demonstrates Ability of The Guardant360 Assay to Predict Patient Response to Immunotherapy in Advanced Gastric Cancer Patients
PR-M07-18-NI-070
1
2
»
